Christopher Wee, MD, a genitourinary medical oncologist at Cleveland Clinic, discusses available androgen receptor inhibitors for the treatment of patients with nonmetastatic castration-resistant prostate cancer, including apalutamide (Erleada) darolutamide (Nubeqa) and enzalutamide (Xtandi). He also explains what is still needed to optimize the use of these agents in this space.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.